Apexigen, a clinical-stage biopharmaceutical company engaged in the discovery and development of a new generation of antibody therapeutics for oncology, has raised $73m in Series B And Series C financings.
Teneobio and Poseida Therapeutics have entered into a new research collaboration and licensing agreement to develop novel CAR-T therapies using Teneobio’s heavy chain only domain antibodies (UniDabs).
Oxford BioMedica has collaborated with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Imperial Innovations for the development of a long-term therapy to treat patients with cystic fibrosis.
Acadia Pharmaceuticals and Neuren Pharmaceuticals have signed an exclusive North American license agreement for the development and commercialization of trofinetide for Rett syndrome and other indications.
BioTime, a clinical-stage biotechnology company focused on degenerative diseases, has announced a new strategic alignment between AgeX Therapeutics and Juvenescence, for which the company will receive $21.6M in cash and $21.6M in a 7% convertible/redeemable note for 14.4M shares of AgeX Therapeutics.
Japanese pharmaceutical company Daiichi Sankyo and clinical-stage immuno-oncology firm Glycotope have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate (ADC).
Eli Lilly and Company has extended its cancer research collaboration with Dana-Farber Cancer Institute for three more years.
Kite and Gadeta have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers.
Cambrex has agreed to acquire contract development and manufacturing organization (CDMO) Halo Pharma for about $425m.
Novartis has agreed to make an upfront payment of EUR95m to Galapagos and MorphoSys to in-license IL-17C compound for atopic dermatitis.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.